• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

色烯并[2,3- c]吡咯-9(2 H)-酮类作为高效、选择性、口服生物利用度的 PDE5 抑制剂的优化:构效关系、X 射线晶体结构及对肺动脉高压的药效学影响。

Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension.

机构信息

School of Pharmaceutical Sciences , Sun Yat-Sen University , Guangzhou 510006 , P. R. China.

出版信息

J Med Chem. 2018 Sep 27;61(18):8468-8473. doi: 10.1021/acs.jmedchem.8b01209. Epub 2018 Sep 7.

DOI:10.1021/acs.jmedchem.8b01209
PMID:30148362
Abstract

To further explore the structure-activity relationship around the chromeno[2,3- c]pyrrol-9(2 H)-one scaffold, 19 derivatives as inhibitors against PDE5 were discovered. The most potent inhibitor 3 has an IC of 0.32 nM with remarkable selectivity and druglike profile. Oral administration of 3 (1.25 mg/kg) caused comparable therapeutic effects to sildenafil (10.0 mg/kg) against pulmonary arterial hypertension. Further, different binding patterns from sildenafil were revealed in cocrystal structures, which provide structural templates for discovery of highly potent PDE5 inhibitors.

摘要

为了进一步探索色烯并[2,3-c]吡咯-9(2H)-酮骨架周围的结构-活性关系,发现了 19 种作为 PDE5 抑制剂的衍生物。最有效的抑制剂 3 的 IC 为 0.32 nM,具有显著的选择性和类药性。3(1.25 mg/kg)的口服给药在治疗肺动脉高压方面与西地那非(10.0 mg/kg)相当。此外,在共晶结构中揭示了与西地那非不同的结合模式,为发现高效 PDE5 抑制剂提供了结构模板。

相似文献

1
Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension.色烯并[2,3- c]吡咯-9(2 H)-酮类作为高效、选择性、口服生物利用度的 PDE5 抑制剂的优化:构效关系、X 射线晶体结构及对肺动脉高压的药效学影响。
J Med Chem. 2018 Sep 27;61(18):8468-8473. doi: 10.1021/acs.jmedchem.8b01209. Epub 2018 Sep 7.
2
Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.发现并优化色满并[2,3-c]吡咯-9(2H)-酮作为新型选择性且口服生物可利用的磷酸二酯酶5抑制剂用于治疗肺动脉高压
J Med Chem. 2017 Aug 10;60(15):6622-6637. doi: 10.1021/acs.jmedchem.7b00523. Epub 2017 Jul 25.
3
Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure.发现 3-(4-羟基苄基)-1-(噻吩-2-基)色烯并[2,3-c]吡咯-9(2H)-酮作为磷酸二酯酶-5 抑制剂及其复合物晶体结构。
Biochem Pharmacol. 2014 May 1;89(1):86-98. doi: 10.1016/j.bcp.2014.02.013. Epub 2014 Feb 22.
4
Curcumin analogues inhibit phosphodiesterase-5 and dilate rat pulmonary arteries.姜黄素类似物抑制磷酸二酯酶-5并扩张大鼠肺动脉。
J Pharm Pharmacol. 2015 Jan;67(1):87-95. doi: 10.1111/jphp.12302. Epub 2014 Sep 1.
5
Exploration of the 5-bromopyrimidin-4(3H)-ones as potent inhibitors of PDE5.探索 5-溴嘧啶-4(3H)-酮作为有效的 PDE5 抑制剂。
Bioorg Med Chem Lett. 2013 Sep 1;23(17):4944-7. doi: 10.1016/j.bmcl.2013.06.062. Epub 2013 Jun 29.
6
Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.新型吡唑并嘧啶酮类似物作为5型磷酸二酯酶强效抑制剂的发现
Bioorg Med Chem. 2015 May 1;23(9):2121-8. doi: 10.1016/j.bmc.2015.03.005. Epub 2015 Mar 9.
7
Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure.西地那非可预防舒张性心力衰竭大鼠模型的肺血管内皮功能障碍和肺血管重构。
Circ Heart Fail. 2011 Mar;4(2):198-206. doi: 10.1161/CIRCHEARTFAILURE.110.957050. Epub 2011 Jan 7.
8
In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors.新型 hERG 中性西地那非样 PDE5 抑制剂的计算机辅助设计。
J Biomol Struct Dyn. 2017 Oct;35(13):2830-2852. doi: 10.1080/07391102.2016.1231634. Epub 2016 Oct 6.
9
Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket.发现吴茱萸碱衍生物作为高选择性 PDE5 抑制剂,靶向独特的变构口袋。
J Med Chem. 2020 Sep 10;63(17):9828-9837. doi: 10.1021/acs.jmedchem.0c00983. Epub 2020 Aug 27.
10
Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH).吸入性西地那非作为口服西地那非的替代药物用于治疗肺动脉高压(PAH)。
J Control Release. 2017 Mar 28;250:96-106. doi: 10.1016/j.jconrel.2017.02.003. Epub 2017 Feb 7.

引用本文的文献

1
Discovery and optimization of 4-(imidazo[1,2-a]pyrimidin-3-yl)thiazol-2-amine derivatives as novel phosphodiesterase 4 inhibitors.4-(咪唑并[1,2-a]嘧啶-3-基)噻唑-2-胺衍生物作为新型磷酸二酯酶4抑制剂的发现与优化
Mol Divers. 2025 Jun;29(3):2283-2291. doi: 10.1007/s11030-024-10991-w. Epub 2024 Sep 23.
2
Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives.磷酸二酯酶5抑制剂的进展:揭示当前与未来展望
Pharmaceuticals (Basel). 2023 Sep 6;16(9):1266. doi: 10.3390/ph16091266.
3
Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: Suppression of neuroinflammation by blocking NF-B transcription regulation and activating cAMP/CREB axis.
发现用于治疗血管性痴呆的新型磷酸二酯酶-1抑制剂:通过阻断核因子-κB转录调控和激活环磷酸腺苷/环磷腺苷反应元件结合蛋白轴来抑制神经炎症
Acta Pharm Sin B. 2023 Mar;13(3):1180-1191. doi: 10.1016/j.apsb.2022.09.023. Epub 2022 Oct 4.
4
Structure-based discovery of orally efficient inhibitors unique interactions with H-pocket of PDE8 for the treatment of vascular dementia.基于结构的口服高效抑制剂的发现:与磷酸二酯酶8的H口袋的独特相互作用用于治疗血管性痴呆。
Acta Pharm Sin B. 2022 Jul;12(7):3103-3112. doi: 10.1016/j.apsb.2022.02.012. Epub 2022 Feb 22.
5
Discovery of catalytic-site-fluorescent probes for tracing phosphodiesterase 5 in living cells.用于追踪活细胞中磷酸二酯酶5的催化位点荧光探针的发现。
RSC Adv. 2021 Oct 4;11(51):31967-31971. doi: 10.1039/d1ra06247f. eCollection 2021 Sep 27.
6
Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension.发现具有高选择性且口服可用的基于苯并咪唑的磷酸二酯酶10抑制剂,其溶解度和药代动力学性质得到改善,用于治疗肺动脉高压。
Acta Pharm Sin B. 2020 Dec;10(12):2339-2347. doi: 10.1016/j.apsb.2020.04.003. Epub 2020 Apr 18.